Journal of Clinical Oncology
Articles in this Issue
Investigating gender demographics and equity among hematologists.
1630 Background: Despite a substantial number of women in the field of hematology, representation in leadership roles remains inconsistent with ~50% of wo...
Impact of rituximab maintenance on outcomes in follicular lymphoma: An Indian experience.
e19044 Background: Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) and comprises 9% of total NHL in India. Rituxi...
A scoping review of uptake and interventions in specialty and non-primary care clinical settings.
e22505 Background: Persistent human papillomavirus (HPV) infection significantly increases the risk of developing several cancers, including cervical, ana...
First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
5010 Background: Terbium-161 ( 161 Tb) is a novel radionuclide emitting beta-radiation comparable to lutetium-177 ( 17...
Better together: Synergy of germline and somatic testing in HRR pathway-driven cancers.
10571 Background: Germline and somatic pathogenic variants inform eligibility for poly (ADP-ribose) polymerase inhibitors (PARPi) in breast, ovarian, pros...
Therapy-related myeloid neoplasms: A SEER database analysis of residential distribution on overall survival.
e18605 Background: Therapy-related myeloid neoplasms (T-MN), now recognized by the WHO, have increased in incidence due to advances in cancer therapies an...
Global trends in soft tissue and extraosseous sarcomas (1980–2021): Regional and economic disparities.
e23509 Background: Sarcoma is one of the rare malignancies arising from bone or soft tissues, shares a incidence of 1% of all cancers across the world. Th...
PD-1/PD-L1 inhibitors as neoadjuvant therapies in resectable non-small cell lung cancer, including their effects in various PD-1 expression subtypes: A meta-analysis.
e20049 Background: The use of PD-1/PD-L1 inhibitors as neoadjuvant agents for resectable non-small cell lung cancer (NSCLC) has shown promising benefits i...
Evaluating the immune landscape in early onset colorectal cancer patients.
e15711 Background: The incidence of early-onset colorectal cancer (EOCRC) is rising, but little is known about the immune microenvironment. Our prior work...
A fragmentomic tumor score algorithm for enhanced minimal residual disease detection and prognostic prediction in bile duct cancer.
e16287 Background: Bile duct cancer (BDC) remains a challenging malignancy with high recurrence rates after surgery, thus minimal residual disease (MRD) d...
SNF-CLIMEDIN: A HECOG prospective randomized trial of digital support and intervention in patients with advanced non-small cell lung cancer (NSCLC)—Final results.
1515 Background: This trial aims to investigate the feasibility and effectiveness of online digital intervention to NSCLC patients in terms of adverse eve...
Genomic landscapes of HR+HER2- metastatic breast cancer: Insights from ctDNA profiling in the U.S. and China.
e13087 Background: Metastatic breast cancer (MBC) treatment, including CDK4/6 inhibitors and endocrine therapy (ET), faces challenges of resistance and pr...
Waterpipe smoking as deregulator of RNA m6A modification and promotor of epithelial-mesenchymal transition to cause oral cancer.
e18059 Background: Oral squamous cell carcinoma (OSCC) is a significant health challenge, particularly in the Indian subcontinent, where it ranks as the s...
Donafenib combined with capecitabine for postoperative adjuvant therapy of biliary malignant tumors with high risk of recurrence: A multi-center, randomized controlled, phase II study.
TPS4223 Background: Biliary Tract Cancer (BTC) is an aggressive malignancy with rising incidence. Surgery is the only curative option, but only 10% of pat...
Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.
8001 Background: Based on the Ph 3 ADAURA study, adjuvant (adj) treatment (Tx) with osi, a 3rd-generation, EGFR-TKI, is So...
<sup>177</sup> Lu-vipivotide tetraxetan PSMA vs cabazitaxel in metastatic castration-resistant prostate cancer: A real-world analysis using the TriNetX database.
e17065 Background: 177 Lu-vipivotide tetraxetan prostate-specific membrane antigen ( 177 Lu-PSMA) has shown promising...
Treatment of poor-risk non seminomatous germ-cell tumors (NSGCT) adapted by tumor marker decline: A 7-year multicenter real-world experience.
5034 Background: Since 2014, adaptation of chemotherapy based on tumor marker decline after the cycle of BEP (Bleomycin, Etoposide, Cisplatin) is a standa...
Serplulimab versus placebo plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Efficacy and safety from the end-of-study analysis of the international phase 3 ASTRUM-005 study.
8093 Background: ASTRUM-005 is a randomized, double-blind, phase 3 trial comparing the efficacy and safety of anti-PD-1 antibody serplulimab plus chemothe...
Investigating a biopsychosocial model of fatigue in patients with neuroendocrine neoplasms.
e23196 Background: Neuroendocrine neoplasms (NEN) are rare malignancies most commonly originating in the gastrointestinal tract, pancreas, or lungs, which...
Measuring pancreatic cancer spatial conformation to predict recurrence risk after total neoadjuvant therapy.
e14626 Background: Despite advancements in neoadjuvant therapy and surgical techniques, patients with pancreatic ductal adenocarcinoma (PDAC) often experi...
Assessing mortality trends among patients with lip and oral cavity cancer due to tobacco consumption: A systematic analysis of the Global Burden of Disease-2021.
e18134 Background: Tobacco is an established risk factor for lip and oral cavity cancer (LOC). While a previous study quantified the global and regional b...
Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM).
9552 Background: Activating NRAS mutations occur in 15-20% of MM cases. The MEK inhibitor binimetinib has modest single agent activity with 15% objective...
<sup>177</sup> Lu-PSMA-617 consolidation therapy post docetaxel in patients with de-novo high-volume metastatic hormone-sensitive prostate cancer: A randomized, phase 2 trial.
5095 Background: De-novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC) presents a therapeutic challenge with a dismal five-year surviva...
Colorectal cancer and sepsis mortality among the elderly: Analysis from 1999 to 2020.
e15592 Background: Sepsis is a major cause of death among adults, especially those with colorectal cancer, a common cancer in older individuals. Despite h...
Incidence and clinical outcomes of sweet syndrome in hospitalized cancer patients.
e23085 Background: Sweet syndrome or febrile neutrophilic dermatosis has been noted to be associated with several underlying conditions such as malignancy...